Journal of Neuro-Oncology

, Volume 133, Issue 1, pp 17–25 | Cite as

Incidence and survival trends in oligodendrogliomas and anaplastic oligodendrogliomas in the United States from 2000 to 2013: a CBTRUS Report

  • Rebecca L. Achey
  • Vishesh Khanna
  • Quinn T. Ostrom
  • Carol Kruchko
  • Jill S. Barnholtz-Sloan
Laboratory Investigation


Measuring tumor-specific trends in incidence is necessary to elucidate tumor-type contribution to overall cancer burden in the US population. Recently, there have been conflicting reports concerning the incidence of oligodendrogliomas (OD) and anaplastic oligodendrogliomas (AOD). Therefore, our goal was to examine trends in OD and AOD incidence and survival by age, gender and race. Data was analyzed from the Central Brain Tumor Registry of the United States (CBTRUS) from 2000 to 2013. Age-adjusted incidence rates per 100,000 person-years with 95% confidence intervals (CI) and annual percent changes (APCs) with 95% CI were calculated for OD and AOD by age, sex and race. Survival rates were calculated for age, sex and race using a subset of the CBTRUS data. OD and AOD incidence peaked at 36–40 and 56–60 years, respectively. AOD:OD ratio increased up to age 75. Overall, OD and AOD incidence decreased [OD: APC −3.2 (2000–2013), AOD: −6.5 (2000–2007)]. OD incidence was highest in Whites but decreased significantly (2000–2013: APC −3.1) while incidence in Black populations did not significantly decrease (2000–2013: APC −1.6). Survival rates decreased with advancing age for OD, while persons aged 0–24 had the lowest survival for AOD. The current study reports a decrease in overall OD and AOD incidence from 2000 to 2013. Furthermore, AOD makes up an increasing proportion of oligodendroglial tumors up to age 75. Lower AOD survival in 0–24 years old may indicate molecular differences in pediatric cases. Thus, surveillance of tumor-specific trends by age, race and sex can reveal clinically relevant variations.


Oligodendroglioma Cancer registries Incidence Survival Time trends 



Funding for CBTRUS was provided by the Centers for Disease Control and Prevention (CDC) under Contract No. 200-2016-M-90304, The Sontag Foundation, Genentech, Novocure, Celldex, AbbVie, along with the Musella Foundation, Voices Against Cancer, Elekta, and the Zelda Dorin Tetenbaum Memorial Fund, as well as private and in kind donations.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Institutional Review Board at University Hospitals Case Medical Center. For this type of study, formal consent was not required.

Informed consent

This was a retrospective study using de-identified national cancer registries. Thus, formal consent was not required.

Supplementary material

11060_2017_2414_MOESM1_ESM.docx (13 kb)
Supplementary material 1 (DOCX 13 KB)


  1. 1.
    Gittleman HR, Ostrom QT, Rouse CD, Dowling JA, de Blank PM, Kruchko CA, Elder JB, Rosenfeld SS, Selman WR, Sloan AE, Barnholtz-Sloan JS (2015) Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010. Cancer 121(1):102–112CrossRefPubMedGoogle Scholar
  2. 2.
    Ostrom QT, Gittleman H, de Blank PM, Finlay JL, Gurney JG, McKean-Cowdin R, Stearns DS, Wolff JE, Liu M, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2016) American brain tumor association adolescent and young adult primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol 18(Suppl 1):i1–i50CrossRefPubMedGoogle Scholar
  3. 3.
    Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C, Barnholtz-Sloan JS (2013) CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol 15(Suppl 2):ii1–i56CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Smith JS, Perry A, Borell TJ, Lee HK, O’Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18(3):636–645CrossRefPubMedGoogle Scholar
  5. 5.
    van den Bent M, Chinot O-L, Cairncross JG (2003) Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro Oncol 5(2):128–138PubMedPubMedCentralGoogle Scholar
  6. 6.
    Uytdewilligen L, Sillevis Smitt PA, Jenkins RB, Kros JM (2003) Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97(5):1276–1284CrossRefPubMedGoogle Scholar
  7. 7.
    Aldape K, Simmons ML, Davis RL, Miike R, Wiencke J, Barger G, Lee M, Chen P, Wrensch M (2000) Discrepancies in diagnoses of neuroepithelial neoplasms: the San Francisco Bay Area Adult Glioma Study. Cancer 88(10):2342–2349CrossRefPubMedGoogle Scholar
  8. 8.
    Burger PC (2002) What is an oligodendroglioma? Brain Pathol 12(2):257–259CrossRefPubMedGoogle Scholar
  9. 9.
    McCarthy BJ, Propp JM, Davis FG, Burger PC (2008) “Time trends in oligodendroglial and astrocytic tumor incidence.” Neuroepidemiology 30(1):34–44CrossRefPubMedGoogle Scholar
  10. 10.
    Arora RS, Alston RD, TOB Eden, Estlin EJ, Moran A, Geraci M, Birch JM (2010) Are reported increases in incidence of primary CNS tumours real? An analysis of longitudinal trends in England, 1979–2003. Eur J Cancer 46(9):1607–1616CrossRefPubMedGoogle Scholar
  11. 11.
    Overview of the Seer Program. In: National Cancer Institute. Accessed 9 Apr 2017
  12. 12.
    Number of Persons by Race and Hispanic Ethnicity for SEER Participants - SEER Registries. In: National Cancer Institute. Accessed 9 Apr 2017
  13. 13.
    Siegel RL, Miller KD, Jemal A (2016) Cancer statistics. CA 66(1):7–30PubMedGoogle Scholar
  14. 14.
    Little MP, Rajaraman P, Curtis RE, Devesa SS, Inskip PD, Check DP, Linet MS (2012) Mobile phone use and glioma risk: comparison of epidemiological study results with incidence trends in the United States. BMJ 344:e1147CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Barchana M, Margaliot M, Liphshitz I (2012) Changes in brain glioma incidence and laterality correlates with use of mobile phones–a nationwide population based study in Israel. Asian Pac J Cancer Prev 13(11):5857–5863CrossRefPubMedGoogle Scholar
  16. 16.
    Engelhard HH, Stelea A, Mundt A (2003) Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol 60(5):443–456CrossRefPubMedGoogle Scholar
  17. 17.
    Arora RS, Alston RD, TOB. Eden, Estlin EJ, Moran A, Birch JM (2009) Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England. Neuro Oncol 11(4):403–413CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61(3):215–259CrossRefPubMedGoogle Scholar
  19. 19.
    Burger PC, Green SB (1987) Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 59(9):1617–1625CrossRefPubMedGoogle Scholar
  20. 20.
    Kim TS, Halliday AL, Hedley-Whyte ET, Convery K (1991) Correlates of survival and the Daumas-Duport grading system for astrocytomas. J Neurosurg 74(1):27–37CrossRefPubMedGoogle Scholar
  21. 21.
    Jung K-W, Yoo H, Kong H-J, Won Y-J, Park S, Lee SH (2012) Population-based survival data for brain tumors in Korea. J Neurooncol 109(2):301–307CrossRefPubMedGoogle Scholar
  22. 22.
    Sant M, Minicozzi P, Lagorio S, Børge Johannesen T, Marcos-Gragera R, Francisci S, and EUROCARE Working Group (2012) Survival of European patients with central nervous system tumors. Int J cancer 131(1):173–185CrossRefPubMedGoogle Scholar
  23. 23.
    Suri V, Jha P, Agarwal S, Pathak P, Sharma MC, Sharma V, Shukla S, Somasundaram K, Mahapatra AK, Kale SS, Sarkar C (2011) Molecular profile of oligodendrogliomas in young patients. Neuro Oncol 13(10):1099–1106CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Raghavan R, Balani J, Perry A, Margraf L, Vono MB, Cai DX, Wyatt RE, Rushing EJ, Bowers DC, Hynan LS, White CL (2003) Pediatric oligodendrogliomas: a study of molecular alterations on 1p and 19q using fluorescence in situ hybridization. J Neuropathol Exp Neurol 62(5):530–537CrossRefPubMedGoogle Scholar
  25. 25.
    Kreiger PA, Okada Y, Simon S, Rorke LB, Louis DN, Golden JA (2005) Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas. Acta Neuropathol 109(4):387–392CrossRefPubMedGoogle Scholar
  26. 26.
    Jiang H, Ren X, Cui X, Wang J, Jia W, Zhou Z, Lin S (2013) 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas. Neuro Oncol 15(6):775–782CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90(19):1473–1479CrossRefPubMedGoogle Scholar
  28. 28.
    Curry WT, Carter BS, Barker FG (2010) Racial, ethnic, and socioeconomic disparities in patient outcomes after craniotomy for tumor in adult patients in the United States, 1988–2004. Neurosurgery 66(3):427–438CrossRefPubMedGoogle Scholar
  29. 29.
    Barnholtz-Sloan JS, Sloan AE, Schwartz AG (2003) Racial differences in survival after diagnosis with primary malignant brain tumor. Cancer 98(3):603–609CrossRefPubMedGoogle Scholar
  30. 30.
    Tseng M-Y, Tseng J-H, Merchant E (2006) Comparison of effects of socioeconomic and geographic variations on survival for adults and children with glioma. J Neurosurg 105(4 Suppl):297–305PubMedGoogle Scholar
  31. 31.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Nielsen MS, Christensen HC, Kosteljanetz M, Johansen C (2009) Incidence of and survival from oligodendroglioma in Denmark, 1943–2002. Neuro Oncol 11(3):311–317CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Idbaih A, Mokhtari K, Jouvet A, Uro-Coste E, Colin C, Chinot O, Loiseau H, Moyal E, Maurage C-A, Polivka M, Lechapt-Zalcman E, Desenclos C, Meyronet D, Delattre J-Y, Figarella-Branger D, and For POLA Network (2016) Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathol 132:625–634CrossRefPubMedGoogle Scholar
  34. 34.
    Cahill DP, Sloan AE, Nahed BV, Aldape KD, Louis DN, Ryken TC, Kalkanis SN, Olson JJ (2015) The role of neuropathology in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. J Neurooncol 125(3):531–549CrossRefPubMedGoogle Scholar
  35. 35.
    Burger PC, Minn AY, Smith JS, Borell TJ, Jedlicka AE, Huntley BK, Goldthwaite PT, Jenkins RB, and Feuerstein BG (2001) Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 14(9):842–853CrossRefPubMedGoogle Scholar
  36. 36.
    Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820CrossRefPubMedGoogle Scholar
  37. 37.
    Ostrom QT, Gittleman H, Kruchko C, Louis DN, Brat DJ, Gilbert MR, Petkov VI, Barnholtz-Sloan JS (2016) “Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004–2012, varying). J Neurooncol 130:31–42CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Cleveland Clinic Lerner College of MedicineCleveland Clinic FoundationClevelandUSA
  2. 2.Case Comprehensive Cancer CenterCase Western Reserve University School of MedicineClevelandUSA
  3. 3.Central Brain Tumor Registry of the United StatesHinsdaleUSA

Personalised recommendations